Kiffik Biomedical

Executive Summary

Kiffik Biomedical is a pre-clinical stage diagnostics company based in Cambridge, MA, developing the KIFFIK EXP platform—a non-invasive wearable device that continuously monitors molecular biomarkers from interstitial fluid (ISF). Founded in 2021, the company’s technology aims to provide real-time, longitudinal biomarker data to accelerate clinical trials, enable precision medicine, and support companion diagnostic development. By replacing or supplementing traditional blood draws with a wearable sensor, Kiffik’s approach could reduce patient burden, improve data density, and lower trial costs. Currently at pre-clinical stage, the company is validating its sensor technology and preparing for first-in-human studies. Although still early, the platform addresses a clear need in decentralized clinical trials and chronic disease monitoring, with potential applications across oncology, metabolic disorders, and inflammation. The team has yet to disclose funding details but operates in the competitive Cambridge biotech ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round60% success
• Q4 2026First-in-human study initiation70% success
• H2 2026Strategic partnership with a pharmaceutical company50% success